CAVIGLIERA BIVALVA Italia - italiano - Ministero della Salute

cavigliera bivalva

ormihl danet s.a. - dispositivi non compresi nelle classi precedenti - altri

SITAGLIPTIN/METFORMINA GRINDEKS Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sitagliptin/metformina grindeks

as grindeks - metformina e sitagliptina - metformina e sitagliptina

METFORMINA BLUEFISH Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metformina bluefish

bluefish pharmaceuticals ab - metformina - metformina

METFORMINA AUROBINDO Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metformina aurobindo

aurobindo pharma (italia) s.r.l. - metformina - metformina

METFORMINA PENSA Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

metformina pensa

towa pharmaceutical s.p.a. - metformina - metformina

Sitagliptin / Metformin hydrochloride Accord Unione Europea - italiano - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.